Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Medicine

• Publication date

  2015-04-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm.3828PMID 25894829
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perspectives on the past, present, and future of educational psychology

  2016cited by this paper
• Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

  2014cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014cited by this paper
• Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation

  2014cited by this paper
• Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

  2014cited by this paper
• Glucose regulation of glucagon secretion.

  2014cited by this paper
• Tolbutamide Controls Glucagon Release From Mouse Islets Differently Than Glucose

  2013cited by this paper
• Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

  2013cited by this paper
• Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.

  2013cited by this paper
• Improved glycemic control in mice lacking Sglt1 and Sglt2.

  2013cited by this paper
• Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats

  2013cited by this paper
• In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach

  2013cited by this paper
• The SLC2 (GLUT) family of membrane transporters.

  2013cited by this paper
• Betatrophin: a hormone that controls pancreatic β cell proliferation.

  2013cited by this paper
• Role of KATP Channels in Glucose-Regulated Glucagon Secretion and Impaired Counterregulation in Type 2 Diabetes

  2013cited by this paper
• Glucagon regulates its own synthesis by autocrine signaling

  2012cited by this paper
• Adaptive changes of human islets to an obesogenic environment in the mouse

  2012cited by this paper
• Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

  2012cited by this paper
• Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus

  2012cited by this paper
• Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

  2012cited by this paper
• Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats

  2012cited by this paper
• Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.

  2012cited by this paper
• Glucose Transport by Acinar Cells in Rat Parotid Glands

  2012cited by this paper
• SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

  2011cited by this paper
• Transcriptomes of the major human pancreatic cell types

  2011cited by this paper
• In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

  2010cited by this paper
• Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

  2010cited by this paper
• Upgrading Pretransplant Human Islet Culture Technology Requires Human Serum Combined With Media Renewal

  2010cited by this paper
• Efficient gene delivery and silencing of mouse and human pancreatic islets

  2010cited by this paper
• Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

  2009cited by this paper
• CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling.

  2009cited by this paper
• Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

  2008cited by this paper
• Sodium glucose co‐transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

  2008cited by this paper
• Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

  2008cited by this paper
• Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells

  2007cited by this paper
• Evidence Based Selection of Housekeeping Genes

  2007cited by this paper
• From mice to men: insights into the insulin resistance syndromes.

  2006cited by this paper
• A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria.

  2005cited by this paper
• Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the U.K. population.

  2004cited by this paper
• A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 alpha gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an ashkenazi jewish population.

  2004cited by this paper
• Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1): Requirement for hepatocyte nuclear factor 4α in gluconeogenesis

  2003cited by this paper
• Hypoglycemia in diabetes.

  2003cited by this paper
• Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis.

  2003cited by this paper
• Identification and Purification of Functional Human β-cells by a New Specific Zinc-fluorescent Probe

  2001cited by this paper
• The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism.

  1997cited by this paper
• Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM

  1995cited by this paper
• Role of Liver in Pathophysiology of NIDDM

  1992cited by this paper
• Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

  1989cited by this paper
• Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus.

  1988cited by this paper
• Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics

  1987cited by this paper
• Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus

  1982cited by this paper
• Donor organs: Mr. Dalyell's bill.

  1979cited by this paper
• Glucagon control of fasting glucose in man.

  1974cited by this paper
• Studies of pancreatic alpha cell function in normal and diabetic subjects.

  1970cited by this paper
• Proliferation

  1966cited by this paper

• Diabetic ketoacidosis is not a simple consequence of hyperglycemia, it is biochemical event driven by PDK4-mediated inhibition of PDC

  2026cites this paper
• Chronic NH4Cl loading improves glucose tolerance without modifying insulin sensitivity in mice

  2026cites this paper
• SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence.

  2026cites this paper
• Renal Protection at a Metabolic Cost: A Systematic Review and Meta-Analysis of Perioperative Use of Sodium-Glucose Cotransporter 2 Inhibitors.

  2026cites this paper
• Euglycemic diabetic ketoacidosis with gastrointestinal dysfunction following lung surgery in a patient on SGLT2 inhibitor: a case report

  2026cites this paper
• Dapagliflozin’s impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial

  2025cites this paper
• A new link between insulinoma and congenital glucose-galactose malabsorption

  2025cites this paper
• Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy

  2025cites this paper
• Non-Diabetic Hypoglycemia: Evaluation and Management in Adults

  2025cites this paper
• Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review

  2025cites this paper
• Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes. Part B: Risks of sodium-glucose co-transporter inhibitor use in type 1 diabetes and ketoacidosis risk mitigation strategies.

  2025cites this paper
• Magnesium Balance in Chronic Kidney Disease: Mineral Metabolism, Immunosuppressive Therapies and Sodium-Glucose Cotransporter 2 Inhibitors

  2025cites this paper
• iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats

  2025cites this paper
• Natrium-Glukose-Co-Transporter-2 (SGLT-2)-Hemmer in der perioperativen Medizin

  2025cites this paper
• A Case of Concurrent Metformin-Associated Lactic Acidosis and Euglycemic Diabetic Ketoacidosis.

  2025cites this paper
• Gene-Expression Programs in Salivary Gland Adenoid Cystic Carcinoma Analyzed Using Single-Cell and Spatial Transcriptomics

  2025cites this paper
• Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives

  2025cites this paper
• Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report

  2025cites this paper
• Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease—2025 Update

  2025cites this paper
• Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications.

  2025cites this paper
• Dehydration-induced AVP stimulates glucagon release and ketogenesis.

  2025cites this paper
• Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings

  2025cites this paper
• Understanding the disease: euglycemic ketoacidosis with SGLT2 inhibitors

  2025cites this paper
• Clinical Management of Euglycemic Ketoacidosis in a Cat With Congenital Diabetes Mellitus Treated With Insulin and Dapagliflozin.

  2025cites this paper
• Early prescription of SGLT2i for acute patient care: from current evidence to future directions.

  2025cites this paper
• Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways

  2025cites this paper
• Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue

  2025cites this paper
• Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review

  2025cites this paper
• Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives

  2025cites this paper
• Neuroprotective effects of medium-chain triglyceride ketogenic diets on type 2 diabetic mice with cognitive disability

  2025cites this paper
• Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities

  2025cites this paper
• The neglected PCK1/glucagon (inter)action in nutrient homeostasis beyond gluconeogenesis: Disease pathogenesis and treatment

  2025cites this paper
• How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review

  2025cites this paper
• Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials

  2025cites this paper
• Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study.

  2025cites this paper
• Clinical research progress on β-cell dysfunction in T2DM development in the Chinese population

  2024cites this paper
• Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1

  2024cites this paper
• Click Reaction Inspired Enzyme Inhibitors in Diabetes Care: An Update in the Field of Chronic Metabolic Disorder.

  2024cites this paper
• Mathematical Models of the Effect of Glucagon on Glycemia in Individuals With Type 2 Diabetes Treated With Dapagliflozin

  2024cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: A Bidirectional Relationship with Clinical and Therapeutic Implications

  2024cites this paper
• Efficacy of Alogliptin/Metformin Fixed-Dose Combination Tablets and Vildagliptin/Metformin Fixed-Dose Combination Tablets on Glycemic Control in Real-World Clinical Practice for the Patients with Type 2 Diabetes: A Multicenter, Open-Label, Randomized, Parallel Group, Comparative Trial

  2024cites this paper
• Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports

  2024cites this paper
• Protective Mechanisms of SGLTi in Ischemic Heart Disease

  2024cites this paper
• The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition

  2024cites this paper
• SGLT2 inhibitors: Exploring the effects in humans and horses

  2024cites this paper
• A Case of Euglycemic Diabetic Ketoacidosis Associated With a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor

  2024cites this paper
• Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction

  2024cites this paper
• Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor “canagliflozin” on the hepatic damage triggered by hypertension in rats

  2024cites this paper
• SGLT-2i associated diabetic ketoacidosis in the setting of cardiogenic shock

  2024cites this paper
• Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus

  2024cites this paper
• Dapagliflozin promotes browning of white adipose tissue through the FGFR1-LKB1-AMPK signaling pathway

  2024cites this paper
• Use of SGLT inhibitors in type 1 diabetes: the promise and the perils.

  2024cites this paper
• Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care

  2024cites this paper
• A Case of Type 2 Diabetes Mellitus with Lung Cancer Suffered from Euglycemic Diabetic Ketosis Accompanied by Adrenal Insufficiency after Immune Checkpoint Inhibitors

  2024cites this paper
• SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits

  2024cites this paper
• Ketoacidosis and SGLT2 Inhibitors: A Narrative Review

  2024cites this paper
• Amelioration effect of dietary vitamin E on ovarian aging in quails: Integrated transcriptome and metabolome

  2024cites this paper
• Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications

  2024cites this paper
• Research progress of isoquercitrin in the treatment of diabetes and its complications

  2024cites this paper
• The endoplasmic reticulum plays a key role in α-cell intracellular Ca2+ dynamics and glucose-regulated glucagon secretion in mouse islets

  2024cites this paper
• Re-emergence of a forgotten diabetes complication: Euglycemic diabetic ketoacidosis

  2024cites this paper
• Pathogenesis of euglycemic ketoacidosis associated with SGLT2 inhibitors

  2024cites this paper
• The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review

  2024cites this paper
• Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials

  2024cites this paper
• Therapeutic effects of a walnut-derived peptide on NLRP3 inflammasome activation, synaptic plasticity, and cognitive dysfunction in T2DM mice.

  2024cites this paper
• From sugar binders to diabetes fighters: the lectin saga of antihyperglycemic activity through systematic review and meta-analysis

  2024cites this paper
• Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.

  2024cites this paper
• Recent Advances in Perioperative Care of Patients using New Antihyperglycaemic Drugs and Devices Dedicated to Diabetes.

  2024cites this paper
• Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease.

  2024cites this paper
• Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study

  2024cites this paper
• Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway

  2024cites this paper
• Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia

  2024cites this paper
• Underlying mechanisms of ketotherapy in heart failure: current evidence for clinical implementations

  2024cites this paper
• Dysregulated renal tubular handling of filtered glucose in patients with type 2 diabetes mellitus: A descriptive study.

  2024cites this paper
• Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease

  2024cites this paper
• Exploring the Effects of Metabolism-Disrupting Chemicals on Pancreatic α-Cell Viability, Gene Expression and Function: A Screening Testing Approach

  2023cites this paper
• Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes

  2023cites this paper
• Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice

  2023cites this paper
• Alpha cells as targets for incretin therapy

  2023cites this paper
• The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review

  2023cites this paper
• Ketone Production and Excretion Even During Mild Hyperglycemia and the Impact of Sodium-Glucose Co-transporter Inhibition in Type 1 Diabetes.

  2023cites this paper
• Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications.

  2023cites this paper
• [Clinical effectiveness and pharmacokinetics of gliflozin from the point of view of individual genetic characteristics: A review].

  2023cites this paper
• Genetic and clinical characterization of familial renal glucosuria

  2023cites this paper
• SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.

  2023cites this paper
• Case Report: Chest Pain as an Uncommon Presentation for Euglycemic Diabetic Ketoacidosis in a Female Patient Using SGLT2 inhibitor

  2023cites this paper
• Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

  2023cites this paper
• Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors

  2023cites this paper
• Empagliflozin improves cardiac function in rats with chronic heart failure

  2023cites this paper
• Metabolic regulation of glucagon secretion.

  2023cites this paper
• Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate–activated Citrate Synthase

  2023cites this paper
• Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs.

  2023cites this paper
• Dapagliflozin Causing Euglycemic Diabetic Ketoacidosis

  2023cites this paper
• Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review

  2023cites this paper
• Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis

  2023cites this paper
• α-cell electrophysiology and the regulation of glucagon secretion

  2023cites this paper
• Exogenous ketone therapy for heart failure: A review

  2023cites this paper
• Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives.

  2023cites this paper
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

  2023cites this paper